SYNC-T prostate cancer treatment shows encouraging long-term survival as LEGION-100 trial expands
Syncromune's SYNC-T therapy shows 80% two-year survival in a Phase 1 metastatic prostate cancer trial. Explore results and Phase 2a plans.
Pharma & Biotech
Pharma & Biotech
Could ATI-052 offer a new approach to asthma and eczema? Phase 1b findings support further testing
Aclaris Therapeutics' ATI-052 shows promising Phase 1b asthma and eczema results. Explore the clinical findings and upcoming Phase 2b plans.
Pharma & Biotech
Tremont AI partners with AstraZeneca to develop AI models for preclinical drug safety assessment
Tremont AI partners with AstraZeneca to develop preclinical safety models, targeting rare toxicity signals and more consistent pathology assessment.
Pharma & Biotech
Array Skin Therapy opens first Houston clinic to expand narrowband UVB treatment access
Array Skin Therapy opens its first Houston clinic, expanding narrowband UVB treatment access for psoriasis, vitiligo and eczema patients.
Pharma & Biotech
Alpheus Medical reports early LDH biomarker findings from 15-patient glioblastoma study
Alpheus Medical reports LDH biomarker findings in 15 glioblastoma patients. The early signal could aid MRI interpretation but needs validation.
Pharma & Biotech
Orphan Therapeutics Accelerator licenses OTXL-101 gene therapy to revive development for rare paediatric disease
Orphan Therapeutics Accelerator licenses OTXL-101 for OTC deficiency, reviving a rare disease gene therapy with early human data and major hurdles ahead.
Pharma & Biotech
AbbVie submits FDA application for etentamig after Phase 3 CERVINO success in multiple myeloma
AbbVie seeks FDA approval for etentamig after Phase 3 myeloma results showed a 60% reduction in progression risk. Infection safety remains in focus.
Pharma & Biotech
Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?
Omabit raises $2 million from Bright Ventures to connect clinical and genomic data for drug development decisions. Validation and adoption remain key.
Pharma & Biotech
Orbis names a new CEO after its $1.4bn billion Novo Nordisk deal, but can AI-designed macrocycles replace injections?
Orbis names Joanne Smith-Farrell CEO after its $1.4 billion Novo Nordisk partnership. The next test is advancing AI-designed oral macrocycles.
Pharma & Biotech
Stevanato Group and Aptar Pharma partner to accelerate prefilled syringe system selection for biologics
Stevanato and Aptar will test prefilled syringe systems for biologics, examining plunger forces and container integrity under USP 382 expectations.